Rader says that even in a worst-case scenario, it might be possible to get the Amgen or Regeneron-Sanofi drugs approved for some limited slice of population before big studies, already started by both companies, to prove they reduce heart attacks and strokes are complete.
FORBES: Merck's Big Vytorin Study Could Change Rules For New Cholesterol Drugs